Prisma Health Cancer Institute, ITOR, CRU
Prisma Health Cancer Institute, ITOR, CRU
Greenville, South Carolina, United States2 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric cancer, gastric neoplasm, neoplasm, stomach disorder | Recruiting | Phase 3 | 2026-08-10 | NCT06731478 | |
| Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, digestive system disorder, digestive system neoplasm, endocrine system disorder, gastric cancer, gastric neoplasm, lung disorder, lung neoplasm, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, non-small cell lung carcinoma, pancreas disorder, pancreatic neoplasm, respiratory system disorder, respiratory tract neoplasm, stomach disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-07-30 | NCT06710132 |